- Visceral Fat Reduction: Its primary clinical use is reducing excess deep abdominal fat.
- GHRH Analog: Tesamorelin mimics natural GHRH but is structurally modified to resist enzymatic breakdown, allowing for a longer half-life in the body.
- Metabolic Support: It increases IGF-1 (Insulin-like Growth Factor 1) levels, which research suggests may improve lipid profiles and overall body composition.
- FDA Indication: Under the brand name Egrifta, it is officially FDA-approved to treat HIV-associated lipodystrophy (abnormal fat distribution).
- Off-Label Use: In functional medicine and anti-aging clinics, it is sometimes utilized off-label for non-HIV patients looking to reduce stubborn abdominal fat and improve metabolic markers.
- Tesa/Ipamorelin (Tesa/Ipa): Ipamorelin is a Growth Hormone Secretagogue (GHRP) that works with Tesamorelin to enhance natural growth hormone pulsatility without spikes in cortisol or prolactin.
- Tesa/Ipa/MOTS-c: This combination adds MOTS-c (a mitochondrial peptide) to improve cellular energy, insulin sensitivity, and nutrient processing alongside fat loss.



